EU Authorization Before US? Biologics Manufacturing Is Likely To Blame

 
• By Bridget Silverman

In the infrequent cases when EU authorization precedes US FDA approvals of new products, biologics manufacturing issues are usually to blame, a Pink Sheet analysis found.

Most new products are approved in the US before the European Union, but those authorized in Europe first mostly are biologics. (Shutterstock)

More from Regional Comparisons

More from Complete Response Letters